Publication date: Mar 24, 2025
Post-acute sequelae of SARS-CoV-2 infection (PASC) represent a significant challenge in patient care, with symptoms persisting beyond three month’s post-recovery. This study aimed to evaluate the incidence of PASC at one year post-COVID-19 and identify predictive biomarkers and comorbidities for effective risk stratification. A cohort of 120 adult patients, including 50 intensive care and 70 non-intensive care patients, was followed up at two weeks, six weeks, and one-year post-discharge using structured questionnaires. The study integrated comorbidities and laboratory biomarkers to forecast the risk for PASC. The median age of participants was 56 years, with 40% having moderate to severe comorbidities. A year post-recovery, 32. 8% exhibited post COVID-19 conditions. The most common symptoms were constitutional (16%), respiratory (8. 4%), and neuropsychiatric (2. 5%). Bayesian network analysis indicated significant correlations between constitutional symptoms, rehospitalisation, and biomarkers including C-reactive protein, lactate-dehydrogenase, ferritin, and albumin. This study highlights the prolonged impact of PASC, one-year post infection. It highlights the role of specific biomarkers such as C-reactive protein, lactate-dehydrogenase, ferritin, and albumin in tailoring individual patient care by advancing understanding in post-COVID-19 symptoms prediction. Our findings support the need for further research to refine these insights, which are pivotal for the ongoing care of patients in the aftermath of COVID-19.
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | post-acute sequelae of SARS-CoV-2 infection |
| disease | MESH | COVID-19 |
| disease | MESH | infection |
| disease | IDO | role |
| disease | MESH | Infectious Diseases |
| pathway | REACTOME | Reproduction |
| disease | MESH | sequelae |
| drug | DRUGBANK | Isoxaflutole |
| disease | IDO | acute infection |
| drug | DRUGBANK | Coenzyme M |
| disease | IDO | symptom |
| disease | MESH | autoimmunity |
| disease | MESH | dysbiosis |
| disease | IDO | facility |
| disease | IDO | disposition |
| drug | DRUGBANK | Medical air |
| disease | IDO | history |
| disease | MESH | morbidities |
| disease | MESH | Comorbidity |
| drug | DRUGBANK | Aspartame |
| disease | MESH | reinfection |
| disease | MESH | sore throat |
| disease | MESH | weight loss |
| disease | MESH | dyspnea |
| disease | MESH | anxiety |
| disease | MESH | depression |
| disease | MESH | smell loss |
| disease | MESH | arthralgia |
| disease | MESH | chest pain |
| disease | IDO | algorithm |
| disease | IDO | process |
| disease | MESH | diabetes mellitus |
| disease | MESH | hypertension |